Abstract
Between 1985 and 1998, 161 patients with primary acute myeloid leukemia (AML) received T-replete bone marrow transplantation (BMT) from unrelated donors in Seattle. Median age was 30 (range 1–55) years. Conditioning for BMT consisted of cyclophosphamide and total body irradiation in 154 (96%) cases and graft-versus-host disease prophylaxis was the standard methotrexate and cyclosporine combination in 134 (83%) cases. Median post-transplant follow-up was 2.9 years. Leukemia-free survival (LFS) at 5 years was 50 ± 12% for transplants during first complete remission (n = 16), 28 ± 8% during second CR (n = 40), 27 ± 17% during subsequent CR (n = 8), 7 ± 3% during relapse (n = 81) and 19 ± 10% during primary induction failure (n = 16). The cumulative incidences of relapse were 19%, 23%, 25%, 44% and 63%, for the five groups, respectively. Transplantation during remission, a marrow cell dose above 3.5 × 108/kg, and cytomegalovirus seronegative status before BMT in both patient and donor were favorable prognostic factors. Adults in any CR who received a marrow cell dose above 3.5 × 108/mg had a LFS of 54 ± 9% at 5 years. These data extend our previous findings on the association between a high marrow cell dose and improved survival and support the use of unrelated donor BMT for treatment of patients with high risk AML when a family match is not available. Bone Marrow Transplantation (2000) 26, 397–404.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gratwohl A, Hermans J . Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation Bone Marrow Transplant 1994 13: 5–10
Gratwohl A, Hermans J . Indications and donor source of hematopoietic stem cell transplants in Europe 1993: report from the European Group for Blood and Marrow Transplantation Clin Transplant 1995 9: 355–363
Gratwohl A, Hermans J, Baldomero H . Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1996 17: 137–148
Gratwohl A, Hermans J, Baldomero H . Blood and marrow transplantation activity in Europe 1995 Bone Marrow Transplant 1997 19: 407–419
Gratwohl A . Blood and marrow transplantation activity in Europe 1996. Special report Bone Marrow Transplant 1998 22: 227–240
Gratwohl A, Passweg J, Baldomero H, Hermans J . Blood and marrow transplantation activity in Europe 1997 Bone Marrow Transplant 1999 24: 231–245
Anasetti C, Petersdorf EW, Martin PJ et al. Improving availability and safety of unrelated donor transplants Curr Opin Oncol 2000 12: 121–126
Petersdorf EW, Gooley T, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient Blood 1998 92: 3515–3520
Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor New Engl J Med 1998 339: 1177–1185
Lamparelli T, Van Lint MT, Gualandi F et al. Bone marrow transplantation for chronic myeloid leukemia from unrelated and sibling donors: single center experience Bone Marrow Transplant 1997 20: 1057–1062
Hessner MJ, Endean DJ, Casper JT et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia Blood 1995 86: 3987–3996
Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose Blood 1997 89: 4226–4235
Hansen JA, Mickelson EM, Choo SY et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In: Rose NR, De Macario EC, Fahey JL et al (eds) Manual of Clinical Laboratory Immunology, 4th edn American Society for Microbiology: Washington, DC 1992 850–867
Dupont B, Yang SY . Histocompatibility. In: Forman SJ, Blume KJ, Thomas ED (eds) Bone Marrow Transplantation Blackwell: Boston, MA 1994 22–40
Petersdorf EW, Smith AG, Mickelson EM et al. Ten HLA-DR4 alleles defined by sequence polymorphism within the DRB1 first domain Immunogenetics 1991 33: 267–275
Storb R, Deeg J, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 1989 73: 1729–1734
Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828
Kaplan EL, Meier P . Nonparametric estimation for incomplete observations J Am Stat Assoc 1958 53: 457–481
Kalbfleish JD, Prentice RL . The Statistical Analysis of Failure Time Data Wiley: New York 1980
Niland JC, Fisher LD . Biostatistical methods in marrow transplantation. In: Forman SJ, Blume KJ, Thomas ED (eds) Bone Marrow Transplantation Blackwell: Boston, MA 1994 242–258
Pepe MS, Longton G, Pettinger M et al. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods Br J Haematol 1993 83: 602–607
Clift R, Goldman J, Gratwohl A, Horowitz M . Proposals for standardized reporting of results of bone marrow transplantation for leukaemia Bone Marrow Transplant 1989 4: 445–448
Busca A, Anasetti C, Anderson G et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia Blood 1994 83: 3077–3084
Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children Blood 1995 86: 3247–3256
Ringdén O, Labopin M, Gluckman E et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis Bone Marrow Transplant 1997 19: 963–968
Consensus panel . A consensus statement on unrelated donor bone marrow transplantation from the consensus panel chaired by EC Gordon-Smith Bone Marrow Transplant 1997 19: 959–962
Rowe JM, Liesveld JL . Treatment and prognostic factors in acute myeloid leukaemia Baillières Clin Haematol 1996 9: 87–105
Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 1998 58: 4173–4179
Gale RP, Horowitz MM, Weiner RS et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myeloid leukemia in first remission Bone Marrow Transplant 1995 16: 203–208
Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission. A European Group for Blood and Marrow Transplantation study Blood 1997 90: 2931–2938
Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial Blood 1998 92: 2322–2333
Labopin M, Gorin NC . Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study Leukemia 1993 6: (Suppl. 4) 95–99
Goldman JM, Schmitz N, Niethammer D, Gratwohl A . Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: current practice in Europe in 1998 Bone Marrow Transplant 1998 21: 1–7
Hansen JA, Gooley T, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia New Engl J Med 1998 338: 962–968
Demirer T, Gooley T, Buckner CD et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation Bone Marrow Transplant 1995 15: 907–913
Neiderwieser D, Pepe M, Storb R et al. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia Br J Haematol 1988 69: 23–28
Bortin M, Gale RP, Kay HEM, Rimm AA . Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality JAMA 1983 249: 1166–1172
Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies Blood 1996 88: 3223–3229
Dini G, Lamparelli T, Rondelli D et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia Br J Haematol 1998 102: 544–552
Anderlini P, Korbling M, Sale D et al. Allogeneic blood stem cell transplantation: considerations for donors Blood 1997 90: 903–908
Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases Bone Marrow Transplant 1996 18: 35–40
Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow Blood 1996 88: 2775–2779
Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation Blood 1999 94: 455–464
Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease Blood 1997 90: 4705–4709
Solano C, Martínez C, Brunet S et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study Bone Marrow Transplant 1998 22: 1129–1135
Acknowledgements
This work was supported in part by National Institutes of Health grants CA18029, CA18221, CA15704 and AI33484. Dr Sierra is a recipient of grant FIS 97/0626 from the Fondo de Investigaciones Sanitarias del Ministerio de Sanidad y Consumo, Spain. We would like to thank Amy Mellon for data management and Jennifer Brackensick for her skillful assistance in the preparation of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sierra, J., Storer, B., Hansen, J. et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26, 397–404 (2000). https://doi.org/10.1038/sj.bmt.1702519
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702519
Keywords
This article is cited by
-
Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia
BMC Cancer (2021)
-
Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia
Annals of Hematology (2019)
-
Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy
Bone Marrow Transplantation (2017)
-
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes
Bone Marrow Transplantation (2013)
-
Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin
Bone Marrow Transplantation (2013)